Clinical trials: Systemic Lupus
Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases.
- Conditions
- Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases, Auto-inflammatory Dermatological Diseases, Skin Diseases
- Trial name
- TekAPo (NCT06387654)
- Testing
- Blood sampling, Remainders of samples taken as part of the treatment
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Systemic Lupus Erythematosus
An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
This is a monocenter, open-label Phase II trial for refractory SLE patients currently on stable background immunosuppressive therapy. Treatment in this trial will be daratumumab weekly for a period of 8 weeks.
- Trial name
- DARALUP (NCT04810754)
- Testing
- Daratumumab Injection
- Volunteers
- 10 people
- Sponsor
- Charite University, Berlin, Germany
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus
Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study
Systemic lupus erythematosus (SLE) is severe, chronic, disabling autoimmune disease that significantly affects health status and quality of life.
- Trial name
- NCT00342095
- Where
- 6 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Systemic Lupus Erythematosus (SLE)
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
This Phase 4 study is being performed to examine the effects of Acthar for the indicated use of treatment of SLE. This study will enroll patients with steroid-dependent, persistently active SLE with arthritic and/or cutaneous…
- Trial name
- NCT01753401
- Testing
- Acthar, Steroid Drug
- Where
- 22 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mallinckrodt
Systemic Lupus Erythematosus
Myfortic Versus Azathioprine in Systemic Lupus Erythematosus
This study is designed to explore the use of myfortic ® in patients with active lupus erythematosus. Similar drugs in this class are increasingly used in organ transplantation and in autoimmune diseases.
- Trial name
- NCT00504244
- Testing
- switch to Myfortic, continuation of azathioprine
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Erasmus Medical Center
Lupus Nephritis
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.
- Trial name
- BLISS-LN (NCT01639339)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 448 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
Expression of CXCR4 in Patients With Systemic Lupus Erythematosus
The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.
- Trial name
- NCT04799730
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Systemic Lupus Erythematosus
Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)
While glucocorticoids and immunosuppressants ameliorate manifestations of SLE in many patients, current therapies are insufficient to control the disease in a subset of patients, and their clinical prognosis remains poor due to…
- Trial name
- ASSIST (NCT00750971)
- Testing
- Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
- Where
- 8 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Systemic Lupus Erythematosus
Saphnelo Use in Females of Child-bearing Potential
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by substantial clinical burden-including organ damage, increased morbidity, and mortality-that often presents in young adulthood and…
- Trial name
- PRIMULA DUS (NCT07431775)
- Testing
- Anifrolumab
- Volunteers
- 26,000,000 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Systemic
Efficacy and Safety of Telitacicept in Early SLE
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with early stage of SLE .
- Trial name
- NCT05899907
- Testing
- Telitacicept, Standard of Care
- Where
- 20 sites in China
- Volunteers
- 180 people
- Sponsor
- Peking Union Medical College Hospital
Systemic Lupus Erythematosus
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
- Trial name
- NCT00732940
- Testing
- Belimumab 100 mg SC
- Where
- 11 sites in United States, Mexico
- Volunteers
- 56 people
- Sponsor
- Human Genome Sciences Inc.
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.
- Trial name
- NCT02780674
- Testing
- MEDI7734
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus, Quality of Life
Peer Approaches to Lupus Self-management
The Peer Approaches to Lupus Self-Management (PALS) study is a randomized, controlled in which 360 African American women with lupus will be recruited from the MUSC SLE database (60 mentors and 300 mentees).
- Conditions
- Systemic Lupus Erythematosus, Quality of Life, Behavior, Health
- Trial name
- PALS (NCT03734055)
- Testing
- Peer Mentoring, Social Support Group
- Where
- United States
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Lupus Nephritis, Lupus Erythematosus
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis.
- Trial name
- MSV_LE (NCT03673748)
- Testing
- Mesenchymal stem cells (MSC)
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Red de Terapia Celular
Immune Thrombocytopenia, System; Lupus Erythematosus
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune- mediated acquired bleeding disorder, defined as a platelet count less than 100×109/L without other causes of isolated thrombocytopenia.
- Trial name
- NCT07298733
- Testing
- measuring gene expression
- Volunteers
- 300 people
- Sponsor
- Sohag University
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are…
- Trial name
- ALLEGORY (NCT04963296)
- Testing
- Obinutuzumab, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride
- Where
- 64 sites in United States, Argentina and 12 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
Urinary G3BP as a Novel Biomarker in Lupus Nephritis
Estimation of urinary Galectin-3 binding protein (u-Gal-3BP) in patients with systemic lupus erythematosus with and without lupus nephritis and in glomerulonephritis for other kidney diseases, Find the relation of urinary…
- Trial name
- NCT06520670
- Testing
- Urinary galectin-3 binding protein
- Volunteers
- 70 people
- Sponsor
- Assiut University
Lupus Nephritis
The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
To investigate the efficacy and safety of enteric-coated mycophenolate sodium (Myfortic) as compared to intravenous cyclophosphamide in the treatment of active nephritis.
- Trial name
- CONTROL (NCT01015456)
- Testing
- mycophenolate sodium, cyclophosphamide
- Where
- 3 sites in Thailand
- Volunteers
- 59 people
- Sponsor
- Chulalongkorn University
Lupus Nephritis
RING - Rituximab for Lupus Nephritis With Remission as a Goal
OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at least 6 months of standard of care (SOC).
- Trial name
- RING (NCT01673295)
- Testing
- RTX infusions, Standard of Care
- Where
- Belgium
- Volunteers
- 194 people
- Sponsor
- Frédéric A. Houssiau, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.